{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:53:45Z","timestamp":1790736825955,"version":"4.1.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFA1107400"],"award-info":[{"award-number":["2024YFA1107400"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neoadjuvant treatment for hormone receptor (HR)-positive breast cancer remains limited, particularly for tumors that are insensitive to neoadjuvant chemotherapy. This study aims to compare the efficacy of neoadjuvant endocrine therapy combined with CDK4\/6 inhibitors to that of traditional neoadjuvant chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>A total of 49 patients receiving neoadjuvant endocrine therapy plus CDK4\/6 inhibitors and 210 receiving neoadjuvant chemotherapy were enrolled. Magnetic resonance imaging was performed to assess tumor responses every 2-3 cycles of treatment. Propensity score matching (PSM) was performed to balance baseline characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Both before and after PSM, the objective response rate (ORR) in the endocrine therapy group was comparable to that of the traditional chemotherapy group. After matching, the ORR was 64.6% (95% CI, 49.5-77.8) in the endocrine group and 56.3% (95% CI, 41.2-70.5) in the chemotherapy group (P\u2009=\u2009.532). A higher proportion of patients in the endocrine group achieved a pathological complete or near-complete response (Miller-Payne grades 4-5, 13.5% vs 10.4%) and post-treatment Ki67\u2009&amp;lt;\u20095%, indicating a potential long-term benefit. Patients with \u226530% regression in maximal tumor diameter after 2 cycles of chemotherapy were considered chemotherapy sensitive. Among patients with tumors less sensitive to chemotherapy, sequential treatment with neoadjuvant endocrine therapy plus CDK4\/6 inhibitors significantly improved ORR (61.8% vs 32.4%, P\u2009=\u2009.028) and was associated with greater Ki67 reduction and improved Miller-Payne grades.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Neoadjuvant endocrine therapy is a promising alternative for HR-positive breast cancer, especially for patients with poor responses to chemotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag032","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T12:33:35Z","timestamp":1770122015000},"source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of neoadjuvant endocrine therapy with CDK4\/6 inhibitors in locally advanced breast cancer"],"prefix":"10.1093","volume":"31","author":[{"given":"Mengqi","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing, 100021,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxiao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing, 100021,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing, 100021,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxia","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing, 100021,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing, 100021,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing, 100021,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing, 100021,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilupai","family":"Abudureheiyimu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing, 100021,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuqing","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing, 100021,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing, 100021,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengjuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing, 100021,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuwen","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing, 100021,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing, 100021,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4195-337X","authenticated-orcid":false,"given":"Binghe","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing, 100021,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4547-1266","authenticated-orcid":false,"given":"Qiao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing, 100021,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"2026030218563549900_oyag032-B1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026030218563549900_oyag032-B2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.tem.2023.12.008","article-title":"Targeting systemic and gut microbial metabolism in ER(+) breast cancer","volume":"35","author":"Heath","year":"2024","journal-title":"Trends Endocrinol Metab"},{"key":"2026030218563549900_oyag032-B3","first-page":"477","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026030218563549900_oyag032-B4","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10549-020-05539-z","article-title":"Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence","volume":"180","author":"Lee","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"2026030218563549900_oyag032-B5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(17)30777-5","article-title":"Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials","volume":"19","author":"Asselain","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026030218563549900_oyag032-B6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"key":"2026030218563549900_oyag032-B7","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"2026030218563549900_oyag032-B8","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.23.01994","article-title":"Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes","volume":"42","author":"Rastogi","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026030218563549900_oyag032-B9","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaoncol.2020.2535","article-title":"Association of event-free and distant recurrence-free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 AND 3 breast cancer: Three-year follow-UP analysis for the I-SPY2 adaptively randomized clinical trial","volume":"6","author":"Yee","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026030218563549900_oyag032-B10","doi-asserted-by":"crossref","first-page":"103900","DOI":"10.1016\/j.critrevonc.2022.103900","article-title":"Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives","volume":"181","author":"Sirico","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026030218563549900_oyag032-B11","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet"},{"key":"2026030218563549900_oyag032-B12","doi-asserted-by":"crossref","first-page":"6834","DOI":"10.3390\/ijms24076834","article-title":"A basic review on estrogen receptor signaling pathways in breast cancer","volume":"24","author":"Clusan","year":"2023","journal-title":"IJMS"},{"key":"2026030218563549900_oyag032-B13","doi-asserted-by":"crossref","first-page":"104743","DOI":"10.1016\/j.esmoop.2025.104743","article-title":"189O ribociclib + endocrine treatment vs soc chemotherapy in intermediate risk HR+\/HER2- early breast cancer: Results from the neoadjuvant cohort of the phase-III WSG adaptcycle \u2013 trial","volume":"10","author":"Harbeck","year":"2025","journal-title":"ESMO Open"},{"key":"2026030218563549900_oyag032-B14","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1200\/JCO.2025.43.16_suppl.606","article-title":"Results of the prospective randomized controlled trial VOG-01: neoadjuvant endocrine therapy ribociclib + fulvestrant + GnRH-a versus chemotherapy 4 AC + 4 T for early HR+\/HER2-negative breast cancer in premenopausal patients","volume":"43","author":"Orlova","year":"2025","journal-title":"JCO"},{"key":"2026030218563549900_oyag032-B15","doi-asserted-by":"crossref","first-page":"x219","DOI":"10.1093\/annonc\/mds307","article-title":"Developments in Ki67 and other biomarkers for treatment decision making in breast cancer","volume":"23 Suppl 10","author":"Sheri","year":"2012","journal-title":"Ann Oncol"},{"key":"2026030218563549900_oyag032-B16","doi-asserted-by":"crossref","first-page":"687244","DOI":"10.3389\/fendo.2021.687244","article-title":"The role of Ki67 in evaluating neoadjuvant endocrine therapy of hormone receptor-positive breast cancer","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026030218563549900_oyag032-B17","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0960-9776(03)00106-1","article-title":"A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival","volume":"12","author":"Ogston","year":"2003","journal-title":"Breast"},{"key":"2026030218563549900_oyag032-B18","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nrclinonc.2012.121","article-title":"Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?","volume":"9","author":"Beelen","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"2026030218563549900_oyag032-B19","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1023\/A:1013128213451","article-title":"Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study","volume":"12","author":"Eiermann","year":"2001","journal-title":"Ann Oncol"},{"key":"2026030218563549900_oyag032-B20","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1200\/JCO.2005.04.005","article-title":"Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial","volume":"23","author":"Smith","year":"2005","journal-title":"JCO"},{"key":"2026030218563549900_oyag032-B21","doi-asserted-by":"crossref","first-page":"105186","DOI":"10.1016\/j.ebiom.2024.105186","article-title":"Clinical efficacy of CDK4\/6 inhibitor plus endocrine therapy in HR-positive\/HER2-0 and HER2-low-positive metastatic breast cancer: a secondary analysis of PALOMA-2 and PALOMA-3 trials","volume":"105","author":"Li","year":"2024","journal-title":"EBioMedicine"},{"key":"2026030218563549900_oyag032-B22","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-070909-182917","article-title":"Mechanisms of endocrine resistance in breast cancer","volume":"62","author":"Osborne","year":"2011","journal-title":"Annu Rev Med"},{"key":"2026030218563549900_oyag032-B23","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(20)30165-3","article-title":"Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future","volume":"395","author":"Spring","year":"2020","journal-title":"Lancet"},{"key":"2026030218563549900_oyag032-B24","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1158\/1078-0432.CCR-19-1425","article-title":"Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, phase II neoadjuvant study in HR(+)\/HER2(-) breast cancer","volume":"26","author":"Hurvitz","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026030218563549900_oyag032-B25","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1470-2045(19)30786-7","article-title":"Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial","volume":"21","author":"Prat","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026030218563549900_oyag032-B26","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/cac2.12649","article-title":"A prospective, phase II, neoadjuvant study based on chemotherapy sensitivity in HR+\/HER2- breast cancer-FINEST study","volume":"45","author":"Chen","year":"2025","journal-title":"Cancer Commun (Lond)"},{"key":"2026030218563549900_oyag032-B27","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13058-020-01288-5","article-title":"Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer","volume":"22","author":"Kim","year":"2020","journal-title":"Breast Cancer Res"},{"key":"2026030218563549900_oyag032-B28","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1158\/1078-0432.CCR-22-0068","article-title":"Evaluation of sensitivity to endocrine therapy index (SET2,3) for response to neoadjuvant endocrine therapy and longer-term breast cancer patient outcomes (Alliance Z1031)","volume":"28","author":"Suman","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026030218563549900_oyag032-B29","doi-asserted-by":"crossref","first-page":"6171","DOI":"10.1007\/s00432-023-04588-3","article-title":"Neoadjuvant endocrine therapy with or without palbociclib in low-risk patients: a phase III randomized double-blind SAFIA trial","volume":"149","author":"Alsaleh","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026030218563549900_oyag032-B30","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1200\/JCO.22.01816","article-title":"De-escalated neoadjuvant trastuzumab-emtansine with or without endocrine therapy versus trastuzumab with endocrine therapy in HR+\/HER2+ early breast cancer: 5-year survival in the WSG-ADAPT-TP trial","volume":"41","author":"Harbeck","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag032\/66799629\/oyag032.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/3\/oyag032\/66799629\/oyag032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/3\/oyag032\/66799629\/oyag032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T23:56:48Z","timestamp":1772495808000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag032\/8466438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,5]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag032","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,2,5]]},"article-number":"oyag032"}}